leisure time -WSS

leisure time

author：hotspot 2025-09-27 22:47:06 - browse：1784

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Intellia plays down concerns on accidental germline transmission

WSS

Medicare Advantage insurers face 0.2% cut to 2025 payments

Readout Newsletter: The latest on Novavax, Merck, Bluebird

CDC says it’s too soon to assess risk posed by Covid subvariant

Study: Spinal cord stimulation helps patients with paralysis walk again

Trans patients at the end of life deserve respect and dignity

FDA greenlights medical device to combat bladder issues

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA greenlights medical device to combat bladder issues

ChatGPT in medicine: STAT answers readers' burning questions

Medicare drug price negotiation legal challenge met with skepticism

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How the drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

10 reasons why health care startups fail

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

hotspot

Investment in vaccine development is lagging, report finds

Abortion policy in the spotlight at Republican debate

Health Care Service Corp to buy Cigna Medicare Advantage plans

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

White House pharmacy plagued with problems, investigation finds

Humana’s losses in Medicare Advantage tank its stock

Wikipedia

explore

focus

leisure time